Disease relevance of Marcellomycin

• In contrast, marcellomycin was not an effective inducer of differentiation of Friend murine erythroleukemia cells [1].
• Human acute promyelocytic leukemia cells (HL-60) were induced to undergo terminal differentiation by treatment in vivo with marcellomycin [2].
• Marcellomycin is a strong inhibitor of the Escherichia coli RNA polymerase-catalyzed synthesis of RNA from the strong A promoters of bacteriophage T7 DNA [3].
• Marcellomycin given on a weekly dose schedule has unpredictable and erratic hematologic toxicity [4].

High impact information on Marcellomycin

• Inhibition of glycoprotein biosynthesis by the inducers of HL-60 cell differentiation, aclacinomycin A and marcellomycin [5].
• After single i.v. doses of the 10% lethal dose, marcellomycin (15 mg/kg) did induce mammary tumors in female Sprague-Dawley rats, whereas aclacinomycin A (15 mg/kg) proved to be nontumorigenic [6].
• Marcellomycin, a newly developed anthracycline antibiotic with antineoplastic activity, was tested as an inducer of differentiation of the human promyelocytic leukemia cell line HL-60 in vitro [1].
• Cells exposed to marcellomycin exhibited a 35-fold increase in their total superoxide anion-generating capacity, an 80% increase in acid phosphatase activity, and a loss of myeloperoxidase and chloroacetate esterase activities [1].
• Marcellomycin is also responsible for minor inhibition of the formation of the open binary RNA polymerase-template complex, which serves as the precursor of the ternary complex [3].

Biological context of Marcellomycin

• A comparison of the effect on protein incorporation of 3H-alanine and cell proliferation by various anthracycline antitumor antibiotics in a concentration range of 50-200 ng/ml revealed that two other N-alkylated anthracyclines, pyrromycin and marcellomycin, are also potent inhibitors of the incorporation of amino acids into proteins [7].
• Human pharmacokinetics of marcellomycin [8].
• This phase I trial was designed to determine the maximum tolerated dose of marcellomycin at a single-dose schedule [9].

Anatomical context of Marcellomycin

• Cisplatin, carboplatin, spiroplatin, and marcellomycin caused no reduction in the neutrophil counts, representing four (24%) of 17 false negatives [10].
• The thermodynamic parameters of the interaction of the two anthracyclines 13-dihydrodaunomycin and marcellomycin with calf thymus DNA were examined by equilibrium binding studies [11].

Associations of Marcellomycin with other chemical compounds

• The effects of marcellomycin, musettamycin, and their respective position 10 epimers mimimycin and collinemycin were compared in several systems both in vivo and in vitro [12].

Analytical, diagnostic and therapeutic context of Marcellomycin

• In conjunction with two phase I clinical trials, we have investigated the pharmacokinetics of marcellomycin (MCM), a new class II anthracycline antibiotic, in nine patients with normal renal and hepatic functions and no third-space fluid accumulation [8].
• Marcellomycin is a new anthracycline that was proposed for clinical trials on the basis of experimental data suggesting reduced potential for hematologic and cardiac toxicity as compared to conventional anthracyclines [9].

References